FindTrial
Sign In

Ultrasonic waves for healing of patients with diabetic foot ulcer

A double blind, randomized,controlled,multicentric study to evaluate and compare the efficacy and safety of GlyBetaC aerostimulator in combination with standard treatment versus a placebo added to standard treatment in patients with diabetic foot ulcer - GlyBetaC

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/09/009785
Enrollment
100
Registered
2017-09-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Improvement is there

Interventions

Intervention1: Glybetac: Ultrasonographic medical device Control Intervention1: USG machine: Placebo with no sonographic waves

Sponsors

MASER ELECTRONICS PVT LTD SPONSORED CLINICAL TRIAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: diabetic foot ulcers Neuropathic Wagner 2 and 3

Exclusion criteria

Exclusion criteria: 1.Ulcers of non-diabetic etiology on the study foot 2.patients with ischemic heart disease and heart failure,psychiatric disorders,hepatic disease,kidney disease,any significant comorbid disease,history of chronic alcoholisum,pregnant women,clinical evidence of gangrene on any part of the affected foot,Patients who have participated in any other clinical trial over the past 3 months

Design outcomes

Primary

MeasureTime frame
50% decrease in wound area healing of ulcerTimepoint: At 4 weeks—

Secondary

MeasureTime frame
50% decrease in ulcer areaTimepoint: 4 weeks—

Countries

India

Contacts

Public ContactDr Ashu Rastogi

PGIMER

ashuendo@gmail.com9781001046

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026